K-Phos No. 2 305 mg/1
Potassium Phosphate, Monobasic and Sodium Phosphate, Monobasic, Anhydrous · TABLET, COATED · Beach Products, Inc.
K-Phos No. 2 is a tablet, coated containing potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous at 305 mg/1, taken oral. Manufactured by Beach Products, Inc..
Key Facts
- Brand Name
- K-Phos No. 2
- Generic Name
- Potassium Phosphate, Monobasic and Sodium Phosphate, Monobasic, Anhydrous
- NDC Code (Product)
0486-1134- Manufacturer
- Beach Products, Inc.
- Strength
- 305 mg/1
- Dosage Form
- TABLET, COATED
- Route
- ORAL
- Marketing Status
- Marketing Start
- 05/09/1978
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATONS AND USAGE K-PHOS® No. 2 is a highly effective urinary acidifier for use in patients with elevated urinary pH. This product helps keep calcium soluble and reduces odor and rash caused by ammoniacal urine. Also, by acidifying the urine, it increases the antibacterial activity of methenamine mandelate and methenamine hippurate.
Dosage & Administration
DOSAGE AND ADMINISTRATION One tablet four times daily with a full glass of water. When the urine is difficult to acidify, administer one tablet every two hours not to exceed 8 tablets in a 24-hour period.
Contraindications
CONTRAINDICATIONS This product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.
Drug Interactions
Drug Interactions The use of antacids containing magnesium, aluminum, or calcium in conjunction with phosphate preparations may bind the phosphate and prevent its absorption. Concurrent use of antihypertensives, especially diazoxide, guanethidine, hydralazine, methyldopa, or rauwolfia alkaloid; or corticosteroids, especially mineralocorticoids or corticotropin, with sodium phosphate may result in hypernatremia. Potassium-containing medications or potassium-sparing diuretics may cause hyperkalemia when used wi t h potassium phosphate. Patients should have serum potassium level determinations at periodic intervals. Plasma levels of salicylates may be increased since salicylate excretion is decreased in acidified urine. Administration of monobasic phosphates to patients stabilized on salicylates may lead to toxic salicylate levels.
Adverse Reactions
ADVERSE REACTIONS Gastrointestinal upset (diarrhea, nausea, stomach pain and vomiting) may occur with phosphate therapy. Also, bone and joint pain (possible phosphate-induced osteomalacia) could occur. The following adverse effects may be observed (primarily from sodium or potassium): headaches; dizziness; mental confusion; seizures; weakness or heaviness of legs; unusual tiredness or weakness; muscle cramps; numbness, tingling, pain, or weakness of hands or feet; numbness or tingling around lips; fast or irregular heartbeat; shortness of breath or troubled breathing; swelling of feet or lower legs; unusual weight gain; low urine output; unusual thirst.
Frequently Asked Questions
What is K-Phos No. 2 used for?
K-Phos No. 2 contains Potassium Phosphate, Monobasic and Sodium Phosphate, Monobasic, Anhydrous. It is a tablet, coated taken oral. Consult your doctor for specific uses.
Is K-Phos No. 2 a controlled substance?
K-Phos No. 2 is not classified as a controlled substance by the DEA.
What is the generic name for K-Phos No. 2?
The generic name for K-Phos No. 2 is Potassium Phosphate, Monobasic and Sodium Phosphate, Monobasic, Anhydrous. There are no other listed brand versions of Potassium Phosphate, Monobasic and Sodium Phosphate, Monobasic, Anhydrous.
What is the NDC code for K-Phos No. 2 305 mg/1?
The NDC (National Drug Code) for K-Phos No. 2 305 mg/1 is 0486-1134, listed by Beach Products, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)